Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER
MS Sabatine, GM De Ferrari, RP Giugliano, K Huber… - Circulation, 2018 - Am Heart Assoc
Background: The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein …
Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein …
Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
ML O'Donoghue, RP Giugliano, SD Wiviott, D Atar… - Circulation, 2022 - Am Heart Assoc
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial
B Gencer, F Mach, SA Murphy, GM De Ferrari… - JAMA …, 2020 - jamanetwork.com
Importance The 2018 American Heart Association/American College of Cardiology
Multisociety Guideline on the Management of Blood Cholesterol identified patients with …
Multisociety Guideline on the Management of Blood Cholesterol identified patients with …
Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial
SA Murphy, TR Pedersen, ZA Gaciong, R Ceska… - JAMA …, 2019 - jamanetwork.com
Importance The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol
and first cardiovascular events in the Further Cardiovascular Outcomes Research With …
and first cardiovascular events in the Further Cardiovascular Outcomes Research With …
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech… - New England journal …, 2017 - Mass Medical Soc
Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
MS Sabatine, RP Giugliano, A Keech, N Honarpour… - American heart …, 2016 - Elsevier
Background Despite current therapies, patients with vascular disease remain at high risk for
major adverse cardiovascular events. Low-density lipoprotein cholesterol is a well …
major adverse cardiovascular events. Low-density lipoprotein cholesterol is a well …
Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already …
RP Giugliano, A Keech, SA Murphy, K Huber… - JAMA …, 2017 - jamanetwork.com
Importance Current guidelines for atherosclerotic cardiovascular disease focus on high-
intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL …
intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL …
Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease
GC Fonarow, AC Keech, TR Pedersen… - JAMA …, 2017 - jamanetwork.com
Importance The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab has been
demonstrated to reduce the composite of myocardial infarction, stroke, or cardiovascular …
demonstrated to reduce the composite of myocardial infarction, stroke, or cardiovascular …
Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER trial
NA Marston, FK Kamanu, F Nordio, Y Gurmu… - Circulation, 2020 - Am Heart Assoc
Background: The ability of a genetic risk score to predict risk in established cardiovascular
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial
Importance Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive
statin therapy reduces progression of coronary atherosclerosis in proportion to achieved …
statin therapy reduces progression of coronary atherosclerosis in proportion to achieved …